| Literature DB >> 29078758 |
Unni Gopinathan1,2, Reidun Øvstebø3, Berit Sletbakk Brusletto3, Ole Kristoffer Olstad3, Peter Kierulf3,4, Petter Brandtzaeg3,5,4, Jens Petter Berg3,4.
Abstract
BACKGROUND: Biological interpretation of DNA microarray data may differ depending on underlying assumptions and statistical tests of bioinformatics tools used. We used Gene Set Enrichment Analysis (GSEA) and Ingenuity Pathway Analysis (IPA) to analyze previously generated DNA microarray data from human monocytes stimulated with N. meningitidis and IL-10 ("the model system"), and with meningococcal sepsis plasma before and after immunodepletion of IL-10 ("the patient plasma system"). The objectives were to compare if the two bioinformatics methods resulted in similar biological interpretation of the datasets, and to identify whether GSEA provided additional insight compared with IPA about the monocyte host response to meningococcal activation.Entities:
Keywords: Bioinformatics; Gene expression; Gene set enrichment analysis; Ingenuity pathway analysis; Interleukin-10; Meningococcal sepsis; N. Meningitidis; mRNA
Mesh:
Substances:
Year: 2017 PMID: 29078758 PMCID: PMC5659018 DOI: 10.1186/s12865-017-0229-5
Source DB: PubMed Journal: BMC Immunol ISSN: 1471-2172 Impact factor: 3.615
Experimental conditions from which DNA microarray data was generated
| In vitro experimental model | Experimental conditions | |||
|---|---|---|---|---|
| Model system | Unstimulated (“Ctr”) | 106/mL | 106/mL | 25 ng/mL IL-10 (“IL-10”)a |
| Patient plasma system | Plasma from patients with meningococcal meningitis or mild meningococcemia (“low LPS plasma”) | Plasma from patients with severe meningococcal sepsis or septic shock, depleted for IL-10 (“IL-10 immunodepleted plasma”) | Plasma from patients with severe meningococcal sepsis or septic shock (“patient plasma with IL-10”) | Plasma from patients with meningococcal meningitis or mild meningococcemia, depleted for IL-10 (“low LPS plasma immunodepleted for IL-10”)a |
aData from these experimental conditions were not used in the present study
Gene sets enriched in human monocytes stimulated with N. meningitidis vs control
| Name of hallmark gene set | Descriptiona | FDR | Number of genes in the gene set | Founder gene setsb |
|---|---|---|---|---|
| Interferon alpha response | Genes up-regulated in response to alpha interferon proteins | <0.001 | 97 | 82 |
| Interferon gamma response | Genes up-regulated in response to IFNG | <0.001 | 200 | 82 |
| TNF signaling via NfkB | Genes regulated by NF-kB in response to TNF | <0.001 | 200 | 120 |
| Inflammatory response | Genes defining inflammatory response | <0.001 | 200 | 120 |
| Allograft rejection | Genes up-regulated during transplant rejection | <0.001 | 200 | 190 |
| IL6 JAK-STAT3 signalling | Genes up-regulated by IL6 [via STAT3, e.g., during acute phase response] | <0.001 | 87 | 24 |
| IL2 STAT5 signaling | Genes up-regulated by STAT5 in response to IL2 stimulation | <0.001 | 200 | 13 |
| KRAS signaling down | Genes down-regulated by KRAS activation | <0.001 | 200 | 16 |
| KRAS signaling up | Genes up-regulated by KRAS activation | <0.001 | 200 | 14 |
| Apoptosis | Genes mediating programmed cell death (apoptosis) by activation of caspases | <0.001 | 161 | 80 |
| Complement | Genes encoding components of the complement system, which is part of the innate immune system | 0.001 | 200 | 71 |
| Epithelial mesenchymal transition | Genes defining epithelial-mesenchymal transition, as in wound healing, fibrosis and metastasis | 0.001 | 200 | 106 |
| Coagulation | Genes encoding components of blood coagulation system; also up-regulated in platelets | 0.015 | 138 | 71 |
| Estrogen response late | Genes defining late response to estrogen | 0.007 | 200 | 59 |
| Hypoxia | Genes up-regulated in response to low oxygen levels (hypoxia) | 0.015 | 200 | 87 |
aDescription of the gene sets were obtained by the Molecular Signatures Database
bFounder gene sets constitute the original experiments associating the genes with specified functions or biological processes
Gene sets enriched in human monocytes stimulated with N. meningitidis and IL-10 vs control
| Name of hallmark gene set | Descriptiona | FDR | Number of genes in the gene set | Founder gene setsb |
|---|---|---|---|---|
| Interferon gamma response | Genes up-regulated in response to IFNG | <0.001 | 200 | 82 |
| Interferon alpha response | Genes up-regulated in response to alpha interferon proteins. | <0.001 | 97 | 82 |
| TNF signaling via NfkB | Genes regulated by NF-kB in response to TNF | <0.001 | 200 | 120 |
| Inflammatory response | Genes defining inflammatory response | <0.001 | 200 | 120 |
| IL2 STAT5 signaling | Genes up-regulated by STAT5 in response to IL2 stimulation. | <0.001 | 200 | 13 |
| IL6 JAK-STAT3 signaling | Genes up-regulated by IL6 [via STAT3, e.g., during acute phase response] | <0.001 | 87 | 24 |
| Allograft rejection | Genes up-regulated during transplant rejection | <0.001 | 200 | 190 |
| Complement | Genes encoding components of the complement system, which is part of the innate immune system | <0.001 | 200 | 71 |
| KRAS signaling up | Genes up-regulated by KRAS activation | 0.003 | 200 | 14 |
| KRAS signaling down | Genes down-regulated by KRAS activation | 0.007 | 200 | 16 |
| Apoptosis | Genes mediating programmed cell death (apoptosis) by activation of caspases | 0.007 | 161 | 80 |
| Hypoxia | Genes up-regulated in response to low oxygen levels (hypoxia) | 0.039 | 200 | 87 |
aDescription of the gene sets were obtained from the Molecular Signatures Database
bFounder gene sets constitute the original experiments associating the genes with specified functions or biological processes
Fig. 1Canonical pathways significantly enriched in human monocytes when comparing Nm vs ctr. Significantly enriched canonical pathways were identified with a right-tailed Fisher’s Exact Test that calculates a P-value determining the probability that each canonical pathway associated with the dataset was due to chance alone. The P-values were corrected for multiple testing using the Benjamini-Hochberg method for correcting the FDR. The z-score indicates predicted activation state of the canonical pathway. Blue color or lighter shades of blue indicate a negative z-score and down-regulation of the pathway, and orange color or lighter shades of orange indicate a positive z-score and up-regulation of the pathway. Ratio denotes the number of significantly expressed genes compared with the total number of genes associated with the canonical pathway
Fig. 2Canonical pathways significantly enriched in human monocytes when comparing Nm + IL-10 vs ctr. Significantly enriched canonical pathways were identified with a right-tailed Fisher’s Exact Test that calculates a P-value determining the probability that each canonical pathway associated with the dataset was due to chance alone. The P-values were corrected for multiple testing using the Benjamini-Hochberg method for correcting the FDR. The z-score indicates predicted activation state of the canonical pathway. Blue color or lighter shades of blue indicate a negative z-score and down-regulation of the pathway, and orange color or lighter shades of orange indicate a positive z-score and up-regulation of the pathway. Ratio denotes the number of significantly expressed genes compared with the total number of genes associated with the canonical pathway
Gene sets enriched in human monocytes stimulated with IL-10 immunodepleted plasma vs low LPS plasma
| Name of hallmark gene set | Descriptiona | FDR | Number of genes in the gene set | Founder gene setsb |
|---|---|---|---|---|
| TNF signaling via NfkB | Genes regulated by NF-kB in response to TNF | <0.001 | 200 | 120 |
| Inflammatory response | Genes defining inflammatory response. | <0.001 | 200 | 120 |
| Interferon gamma response | Genes up-regulated in response to IFNG | <0.001 | 200 | 82 |
| Interferon alpha response | Genes up-regulated in response to alpha interferon proteins. | <0.001 | 97 | 82 |
| IL2 STAT5 signaling | Genes up-regulated by STAT5 in response to IL2 stimulation. | <0.001 | 200 | 13 |
| IL6 JAK-STAT3 signaling | Genes up-regulated by IL6 [via STAT3, e.g., during acute phase response. | <0.001 | 87 | 24 |
| KRAS signaling up | Genes up-regulated by KRAS activation. | 0.001 | 200 | 14 |
| Epithelial mesenchymal transition | Genes defining epithelial-mesenchymal transition, as in wound healing, fibrosis and metastasis | <0.001 | 200 | |
| Allograft rejection | Genes up-regulated during transplant rejection. | <0.001 | 200 | 190 |
| MYC targets_v2 | A subgroup of genes regulated by MYC | 0.004 | 58 | 6 |
| Complement | Genes encoding components of the complement system, which is part of the innate immune system. | 0.004 | 200 | 71 |
| Coagulation | Genes encoding components of blood coagulation system | 0.005 | 138 | 71 |
| Apoptosis | Genes mediating programmed cell death (apoptosis) by activation of caspases. | 0.016 | 161 | 80 |
| Estrogen response early | Genes defining early response to estrogen | 0.018 | 200 | |
| KRAS signaling down | Genes down-regulated by KRAS activation. | 0.029 | 200 | 16 |
| Hypoxia | Genes up-regulated in response to low oxygen levels (hypoxia). | 0.031 | 200 | 87 |
| UV response up | Genes up-regulated in response to ultraviolet (UV) radiation | 0.044 | 58 | 16 |
aDescription of the gene sets were obtained from the Molecular Signatures Database
bFounder gene sets constitute the original experiments associating the genes with specified functions or biological processes
Gene sets enriched in human monocytes stimulated with patient plasma with IL-10 vs low LPS plasma
| Name of hallmark gene set | Descriptiona | FDR | Number of genes in the gene set | Founder gene setsb |
|---|---|---|---|---|
| TNF signaling via NfkB | Genes regulated by NF-kB in response to TNF | <0.001 | 200 | 120 |
| Interferon gamma response | Genes up-regulated in response to IFNG | <0.001 | 200 | 82 |
| Inflammatory response | Genes defining inflammatory response | <0.001 | 200 | 120 |
| Interferon alpha response | Genes up-regulated in response to alpha interferon proteins | <0.001 | 97 | 82 |
| IL6 JAK-STAT3 signaling | Genes up-regulated by IL6 [via STAT3, e.g., during acute phase response] | <0.001 | 87 | 24 |
| IL2 STAT5 signaling | Genes up-regulated by STAT5 in response to IL2 stimulation | <0.001 | 200 | 13 |
| MYC targets_v2 | A subgroup of genes regulated by MYC | <0.001 | 58 | 6 |
| Epithelial mesenchymal transition | Genes defining epithelial-mesenchymal transition, as in wound healing, fibrosis and metastasis | <0.001 | ||
| Complement | Genes encoding components of the complement system | <0.001 | 200 | 71 |
| Allograft rejection | Genes up-regulated during transplant rejection | <0.001 | 200 | 190 |
| KRAS signaling up | Genes up-regulated by KRAS activation | 0.001 | 200 | 14 |
| Estrogen response early | Genes defining early response to estrogen | 0.001 | ||
| Coagulation | Genes encoding components of blood coagulation system | 0.001 | 138 | 71 |
| UV response up | Genes up-regulated in response to ultraviolet (UV) radiation | 0.005 | 158 | 16 |
| Hypoxia | Genes up-regulated in response to low oxygen levels (hypoxia) | 0.008 | 200 | 87 |
| Apoptosis | Genes mediating programmed cell death (apoptosis) by activation of caspases | 0.013 | 161 | 80 |
| Unfolded protein response | Genes up-regulated during unfolded protein response, a cellular stress response related to the endoplasmic reticulum | 0.036 | 113 | 22 |
aDescription of the gene sets were obtained from the Molecular Signatures Database
bFounder gene sets constitute the original experiments associating the genes with specified functions or biological processes
Fig. 3Canonical pathways significantly enriched in human monocytes stimulated with IL-10 immunodepleted plasma vs low LPS plasma. Significantly enriched canonical pathways were identified with a right-tailed Fisher’s Exact Test that calculates a P-value determining the probability that each canonical pathway associated with the dataset was due to chance alone. The P-values were corrected for multiple testing using the Benjamini-Hochberg method for correcting the FDR. The z-score indicates predicted activation state of the canonical pathway. Blue color or lighter shades of blue indicate a negative z-score and down-regulation of the pathway, and orange color or lighter shades of orange indicate a positive z-score and up-regulation of the pathway. Ratio denotes the number of significantly expressed genes compared with the total number of genes associated with the canonical pathway
Fig. 4Canonical pathways significantly enriched in human monocytes stimulated with patient plasma with IL-10 vs low LPS plasma. Significantly enriched canonical pathways were identified with a right-tailed Fisher’s Exact Test, that calculates a P-value determining the probability that each canonical pathway associated to the dataset was due to chance alone. The P-values were corrected for multiple testing using the Benjamini-Hochberg method for correcting the FDR, and a P-value of <0.05 was set as threshold for statistical significance. The z-score indicates predicted activation state of the canonical pathway. Blue color or lighter shades of blue indicate a negative z-score and down-regulation of the pathway, and orange color or lighter shades of orange indicate a positive z-score and up-regulation of the pathway. Ratio denotes the number of significantly expressed genes compared with the total number of genes associated with the canonical pathway
Overview and comparison of significantly enriched gene sets in the model system and the patient plasma systema
| Gene sets enriched in Nm + IL-10 vs Nm | Gene sets enriched in patient plasma with IL-10 vs IL-10 immunodepleted plasma | Gene sets enriched in Nm vs Nm + IL-10 | Gene sets enriched in IL-10 immunodepleted plasma vs patient plasma with with IL-10 |
|---|---|---|---|
| Oxidative phosphorylation | Oxidative phosphorylation | TNF signaling | Interferon alpha response |
| MYC Targets_v1 | Peroxisome | KRAS signaling DN | TNF signaling |
| DNA repair | MYC Targets_v1 | Epithelial-mesenchymal transition | UV response |
| Adipogenesis | Adipogenesis | UV response | Interferon gamma response |
| Peroxisome | MYC targets_v2 | Inflammatory response | Allograft rejection |
| MYC targets_v2 | P53 Pathway | Kras signaling up | Kras signaling up |
| P53 Pathway | Reactive oxygen species | Apical surface | Hedgehog signaling |
| Protein secretion | DNA repair | Cholesterol homeostasis | Hallmark angiogenesis |
| Fatty Acid Metabolism | Allograft rejection | Mitotic spindle | |
| Glycolysis | Interferon alpha response | ||
| Bile acid metabolism | Coagulation |
aDetailed reports about the enriched gene sets is available in Additional files 4, 5, 6, 7
Fig. 5Canonical pathways significantly enriched in human monocytes stimulated with Nm + IL-10 vs Nmabc. aSignificantly enriched canonical pathways were identified with a right-tailed Fisher’s Exact Test, that calculates a P-value determining the probability that each canonical pathway associated to the dataset was due to chance alone. The P-values were corrected for multiple testing using the Benjamini-Hochberg method for correcting the FDR. bThe z-score indicates predicted activation state of the canonical pathway. Blue color or lighter shades of blue indicate a negative z-score and down-regulation of the pathway, and orange color or lighter shades of orange indicate a positive z-score and up-regulation of the pathway. cRatio denotes the number of significantly expressed genes compared with the total number of genes associated with the canonical pathway
Fig. 6Mitochondrial dysfunction in IPA in human monocytes. a Expression levels when comparing Nm + IL-10 vs Nm. b Expression levels when comparing Nm vs ctr. c Expression levels when comparing Nm + IL-10 vs ctr
Genes associated with mitochondrial function identified to be regulated by IL-10 in monocytes stimulated by N. meningitidis
| Symbol | Entrez gene name | Location | Type(s) | Fold change1 | ||
|---|---|---|---|---|---|---|
| Nm vs ctr | Nm + IL-10 vs ctr | Nm + IL-10 vs Nm | ||||
| ACO2 | aconitase 2, mitochondrial | Cytoplasm | Enzyme | −1.66 | −1.33 | 1.25 |
| ATP5A1 | ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle | Cytoplasm | Transporter | −1.83 | −1.34 | 1.37 |
| ATP5H | ATP synthase, H+ transporting, mitochondrial Fo complex, subunit d | Cytoplasm | Enzyme | −1.50 | −1.18 | 1.27 |
| BCL2 | B-cell CLL/lymphoma 2 | Cytoplasm | Transporter | NC | NC | −1.46 |
| CASP3 | caspase 3, apoptosis-related cysteine peptidase | Cytoplasm | Peptidase | NC | 1.86 | 1.79 |
| COX7C | cytochrome c oxidase subunit VIIc | Cytoplasm | Enzyme | −1.66 | NC | 1.45 |
| CYB5A | cytochrome b5 type A (microsomal) | Cytoplasm | Enzyme | −1.69 | NC | 1.48 |
| FURIN | furin (paired basic amino acid cleaving enzyme) | Cytoplasm | Peptidase | −2.47 | 1.42 | 3.51 |
| NCSTN | nicastrin | Plasma Membrane | Peptidase | −1.41 | 1.17 | 1.21 |
| NDUFA6 | NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 14 kDa | Cytoplasm | Enzyme | −2.00 | −1.53 | 1.31 |
| NDUFA9 | NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39 kDa | Cytoplasm | Enzyme | 1.28 | 3.10 | 2.43 |
| NDUFA10 | NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10, 42 kDa | Cytoplasm | Transporter | −1.38 | −1.14 | 1.22 |
| NDUFAB1 | NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1, 8 kDa | Cytoplasm | Enzyme | −2.26 | −1.56 | 1.45 |
| NDUFB5 | NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 16 kDa | Cytoplasm | Enzyme | −1.48 | NC | 1.37 |
| NDUFS2 | NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49 kDa (NADH-coenzyme Q reductase) | Cytoplasm | Enzyme | −2.04 | NC | 1.92 |
| NDUFS6 | NADH dehydrogenase (ubiquinone) Fe-S protein 6, 13 kDa (NADH-coenzyme Q reductase) | Cytoplasm | Enzyme | −1.74 | −1.42 | 1.22 |
| NDUFV2 | NADH dehydrogenase (ubiquinone) flavoprotein 2, 24 kDa | Cytoplasm | Enzyme | NC | −1.61 | −1.44 |
| PRDX3 | peroxiredoxin 3 | Cytoplasm | Enzyme | −1.63 | NC | 1.47 |
| SDHB | succinate dehydrogenase complex, subunit B, iron sulfur (Ip) | Cytoplasm | Enzyme | −1.91 | −1.41 | 1.35 |
| TRAK1 | trafficking protein, kinesin binding 1 | Nucleus | Other | −1.29 | NC | 1.25 |
| UCP2 | uncoupling protein 2 (mitochondrial, proton carrier) | Cytoplasm | Transporter | −2.07 | −1.49 | 1.39 |
| UQCR10 | ubiquinol-cytochrome c reductase, complex III subunit X | Cytoplasm | Enzyme | −1.75 | −1.38 | 1.26 |
| VPS9D1 | VPS9 domain containing 1 | Other | Transporter | NC | NC | 1.86 |
1Significantly expressed genes identified with two-way ANOVA, P < 0.05 after correction for multiple testing using the Benjamini-Hochberg method for correcting the false discovery rate [36]. NC denotes P-value >0.05
Fig. 7Mitochondrial dysfunction in IPA before and after immunodepletion of IL-10. a Expression levels when comparing patient plasma with IL-10 vs IL-10 immunodepleted plasma. b Expression levels when comparing patient plasma with IL-10 vs low LPS plasma. c Expression levels when comparing IL-10 immunodepleted plasma vs low LPS plasma